MedPath
HSA Approval

ZADITEN EYE DROPS 0.25 mg/ml

SIN12209P

ZADITEN EYE DROPS 0.25 mg/ml

ZADITEN EYE DROPS 0.25 mg/ml

February 25, 2003

NOVARTIS (SINGAPORE) PTE LTD

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantNOVARTIS (SINGAPORE) PTE LTD

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

SOLUTION

OPHTHALMIC

Medical Information

S01GX08

ketotifen

Manufacturer Information

NOVARTIS (SINGAPORE) PTE LTD

Excelvision Annonay

Active Ingredients

Ketotifen fumarate 0.345mg eqv ketotifen

0.25 mg/ml

Ketotifen

Documents

Package Inserts

Zaditen Eyedrop PI.pdf

Approved: October 8, 2020

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

ZADITEN EYE DROPS 0.25 mg/ml - HSA Approval | MedPath